[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"knee-arthritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:knee-arthritis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,42,71,95,119,146,173,200],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100440801","phase-2-cannabidiol-cbd-in-pain-reduction-for-knee-osteoarthritis-100440801",false,"NCT05020028","Cannabidiol (CBD) in Pain Reduction for Knee Osteoarthritis","The Use of Cannabidiol (CBD) in Pain Reduction for Knee Osteoarthritis. A Double-Blind, Randomized Control Study","Inclusion Criteria:\n\n* Patients presenting with knee osteoarthritis (KL Grade II-III)\n* Knee pain for at least three months, occurring in at least half of the days in that period\n* VAS ≥ 4\n* Patients ages 40-75, inclusive\n* If female patients are pre-menopausal they must be currently practicing effective forms of two types of birth control, which are defined as those, alone or in combination, that result in a low failure rate (less than 1% per year) when used consistently and correctly\n* Male patients must be using an effective form of contraception\n\nExclusion Criteria:\n\n* Knee Injections within the last 3 months (cortisone, PRP, hyaluronic acid)\n* Legally incompetent or mentally impaired (e.g., minors, Alzheimer's subjects, dementia, etc.)\n* Younger than 40 years of age\n* Older than 75 years of age\n* Any patient considered a vulnerable subject: pregnant women or fetuses, children, cognitively impaired adults, prisoners\n* History of cannabis abuse or dependence\n* History of coagulation abnormalities and thromboembolic disease or current abnormal coagulation test values\n* History of stroke or acute coronary syndromes within 3 months\n* Abnormal coagulation profile\n* Renal failure (serum creatinine \\> 250 μmol\u002FL \\[2.83 mg\u002FdL\\]) or liver cirrhosis\n* Patients that have been on opioid management for any reason just prior to the study\n* Patients with known inflammatory arthritis (such as rheumatoid arthritis, gout, pseudogout etc)\n* Patients with a large effusion\n* Patients with a BMI \\> 35\n* Patients meeting the DSM-V for major psychiatric illness, such as bipolar disorder\n* Patients diagnosed with major depression, psychosis, or substance abuse disorder\n* Patients with current or a history of suicidal ideation\n* Breastfeeding females\n* Abnormal LFTs\n* Patients with major neurological disorders, such as dementia, Parkinson's disease, cognitive impairment, epilepsy, history of traumatic brain\u002Fhead injury, or seizures\n* Patients with moderate (Child-Pugh B) and severe hepatic impairment (Child-Pugh C).\n* Patients taking moderate or strong inhibitors of CYP3A4 and CYP2C19 (listed below) concomitantly will be considered for exclusion if determined to be clinically significant by the treating physicians\n* Patients taking strong CYP3A4 and CYP2C19 inducers (listed below) concomitantly will be considered for exclusion if determined to be clinically significant by the treating physicians\n* Patients taking substrates of UTG1A9, UTGB17, CYP2A1, CYP2B6, CYP2C8, CYP2C9 and CYP2C19 (listed below) concomitantly will be considered for exclusion if determined to be clinically significant by the treating physicians","ALL","40 Years","75 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","The purpose of this study is to see if cannabidiol (CBD) orally dissolving tablets (ODTs) can lessen pain, improve function, and improve patient satisfaction in cases of knee osteoarthritis. CBD comes from the cannabis plant and is non-psychoactive (i.e. does not produce a 'high' or altered mental state) as compared to tetrahydrocannabinol (THC), another compound found in cannabis. Researchers are studying different forms of CBD for potential use in treating pain, inflammation, and illnesses.",[28],"Knee Arthritis","RECRUITING","2026-06-05",{"date":32,"type":33},"2026-06-09","ACTUAL",{"date":35,"type":33},"2022-06-22",{"date":37,"type":21},"2027-09",{"name":39,"class":40},"NYU Langone Health","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100638115","phase-4-role-of-suzetrigine-as-a-part-of-a-multimodal-regimen-to-reduce-pain-and-opioid-use-after-total-knee-arthroplasty-100638115","NCT07624526","Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total Knee Arthroplasty","Inclusion Criteria:\n\n* Patients undergoing primary total knee arthroplasty for osteoarthritis of the knee.\n* Patients between the ages of 18 and 95 years.\n\nExclusion Criteria:\n\n* Patients with concurrent and significant injuries to other bones or organs.\n* Patients with local infections.\n* Minors unable to provide informed consent for participation in the study.\n* Subjects who, in the opinion of the investigator, may be non-compliant with study schedules or procedures.\n* Patients with pre-existing immune suppression, where further immune suppression with GCs could warrant unwarranted or unneeded risk.\n* Patients with preoperative opioid use, defined as daily use less than 4 weeks before the index surgery.\n* Patients with a history of severe heart disease (NYHA2), renal failure, or liver dysfunction\n* Patients with active peptic ulcer disease.\n* Patients neurological or psychiatric diseases, potentially influencing pain perception\n* Patients who are pregnant.\n* Patients with a history of alcohol or medical abuse, allergies to glucocorticoids, current daily use of glucocorticoids.\n* Patients who are unable to take NSAIDs.\n* Patients who receive Deep Venous Thrombosis (DVT) prophylaxis different than Aspirin (81mg) twice daily (BID).\n* Patients who have known diabetes mellitus as defined with an A1C greater than 6.5%.\n* Patients currently taking CYP3A inhibitors","18 Years","95 Years",{"count":51,"type":21},75,[53],"PHASE4","This study is a prospective, single-arm interventional trial enrolling patients undergoing total knee arthroplasty (TKA) for knee arthritis. All participants will receive Suzetrigine (brand name Journavx by Vertex Pharma) as part of a standardized multimodal perioperative analgesic regimen in addition to standard of care.",[28,56],"Knee Osteoarthritis",[58,59],"Total knee arthroplasty","Suzetrigine","NOT_YET_RECRUITING","2026-05-28",{"date":63,"type":33},"2026-06-03",{"date":65,"type":21},"2026-07",{"date":67,"type":21},"2028-08",{"name":69,"class":40},"Emory University",3,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":5},"100481049","evaluating-xperience-advanced-surgical-irrigation-100481049","NCT05543941","Evaluating XPERIENCE™ Advanced Surgical Irrigation","Evaluating XPERIENCE™ Advanced Surgical Irrigation on Risk of Periprosthetic Joint Infection: A Multicenter Randomized Controlled Trial","XPERIENCE","Inclusion Criteria:\n\n1. Male and female patients aged 18 years or older\n2. Diagnosis of osteoarthritis, inflammatory arthritis, osteonecrosis, or post-traumatic arthritis to the affected joint.\n3. Primary TKA, THA, and HR\n4. Subjects receiving both cemented or uncemented orthopaedic implants\n5. Willing and able to sign written consent, follow study protocol and attend follow-up\n\nExclusion Criteria:\n\n1. Inability or refusal to sign informed consent form\n2. Non-English or French speaking, and no licensed translator, family member or substitute decision maker available.\n3. Prior arthroplasty procedure to the affected joint\n4. Procedures involving solid HA implants\n5. Oncologic diagnosis to the affected joint.\n6. Non-TKA, THA or HR prosthesis (i.e., hemiarthroplasty, unicompartmental arthroplasty etc.)\n7. Allergy to any of the components of XP Advanced Surgical Irrigation\n8. Allergy to iodine\n9. Presence of concurrent active infection, primary immunodeficiency, history of uncontrolled HIV (CD4 count \\\u003C200 cells\u002FuL), treatment with immunomodulatory medications for malignancy or autoimmune disease (with exception to inflammatory arthritis), chronic glucocorticosteroid use (≥20 mg of prednisone daily for at least 1 month with another cause of immunosuppression), and solid organ and\u002For bone marrow transplantation.\n10. History of septic arthritis to the affected joint within two years of surgery(1).\n11. History of steroid injection to the affected joint within the three months preceding surgery.\n12. Simultaneous bilateral total joint arthroplasty",{"count":80,"type":21},7600,[82],"NA","A prospective, multi-center, double-arm, parallel, interventional, randomized, controlled clinical trial to assess the rate of periprosthetic joint infection (PJI) in patients undergoing primary total knee arthroplasty (TKA), total hip arthroplasty (THA) or hip resurfacing (HR) with XPERIENCE™ (XP) Advanced Surgical Irrigation versus dilute Betadine (DB).",[85,86,56,28],"Hip Osteoarthritis","Hip Arthritis","2026-05-25",{"date":61,"type":33},{"date":90,"type":33},"2023-04-01",{"date":92,"type":21},"2027-12-31",{"name":94,"class":40},"Ottawa Hospital Research Institute",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":104,"phases":4,"briefSummary":105,"conditions":106,"keywords":107,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":41},"100502637","qist-collaborative---arthroplasty-research-cohort-arc-study-100502637","NCT05824845","QIST Collaborative - Arthroplasty Research Cohort (ARC) Study","QIST Collaborative - Arthroplasty Research Cohort (ARC) Study - a Collaborative, Longitudinal Observational Cohort Study of Patients Undergoing Primary Hip and Knee Replacements in the United Kingdom","Inclusion Criteria:\n\nParticipants must meet all of the inclusion criteria:\n\n1. UK Resident\n2. Able to read and understand documentation and questionnaires in English language\n3. Undergoing elective primary hip or knee arthroplasty (THR, TKR or UKR)\n4. Age 18 years or over\n5. Provides the necessary consents relating to data collection and use of study data, data linkage, future research and invitation to involvement in future trials\n\nExclusion Criteria:\n\nProvided a participant meets all of the inclusion criteria, there are no exclusion criteria for the cohort study.",{"count":103,"type":21},5000,"OBSERVATIONAL","The ARC Study is a national observational cohort study to investigate patient reported and clinical outcomes after hip and knee replacements. The study has the following objectives:\n\n1. To evaluate outcomes following hip and knee replacements.\n2. To determine risk factors for adverse outcomes in primary hip and knee replacements.\n3. To identify targets for future research and intervention in patients undergoing primary hip and knee replacements\n4. To provide a resource from which to identify potential participants for future clinical trials, and to use data collected in the ARC Study as comparison or control data for trial participants who have been randomised to receive one or more interventions.\n\nParticipants are recruited and consented online. Patients are invited to participate by collaborating surgical teams nationally in outpatient clinics at the time of being added to a waiting list, in addition to an advertising campaign to recruit patients. They are directed to an online portal where they will be able to review further information.\n\nConsent and data collection is completed electronically through patients entering data online. Baseline demographics and characteristics are recorded, including details of socio-demographics, lifestyle, health status and patient reported outcome measures (PROMs). Patients then undergo hip\u002Fknee replacement and postoperative rehabilitation according to the standard care and protocols of the hospital and the preferences of their treating surgeon.\n\nFollow-up data, including PROMs, is collected via online questionnaires up to two years following surgery. The study will ultimately also enable multiple trials to be embedded within the cohort study, using a 'Trials within Cohorts' (TwiCs) methodology.",[86,28],[108,109],"Hip Replacement","Knee Replacement","2024-11-14",{"date":112,"type":33},"2024-11-18",{"date":114,"type":33},"2023-07-13",{"date":116,"type":21},"2031-05",{"name":118,"class":40},"Northumbria Healthcare NHS Foundation Trust",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":129,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":41},"100566318","phase-4-effect-of-bupivacaine-liposomes-or-bupivacaine-for-femoral-triangle-or-adductor-block-on-analgesia-after-total-knee-replacement-100566318","NCT06653621","Effect of Bupivacaine Liposomes or Bupivacaine for Femoral Triangle or Adductor Block on Analgesia After Total Knee Replacement","Effect of Bupivacaine Liposomes or Bupivacaine for Femoral Triangle or Adductor Block on Analgesia After Total Knee Replacement: a Prospective, Single-center, Simple Randomized, Active-controlled, Single-blind, 2x2 Factorial Design Clinical Study","Inclusion Criteria:\n\n1. Patients with ASAI-ⅲ\n2. Receive a unilateral initial TKA\n3. Age 18-80 years old -\n\nExclusion Criteria:\n\n1. Bilateral TKA surgery\n2. TKA revision surgery\n3. Contraindications for nerve block and intraspinal anesthesia\n4. Allergies to local anesthetics\n5. Diabetic neuropathy\n6. Patients who are unable to cooperate with the evaluation\n7. Chronic use of opioid analgesics\n8. BMI≥35kg\u002Fcm2\n9. Cases of lumbar anesthesia failure requiring general anesthesia surgery\n10. Cases of nerve block failure\n\n    \\-","80 Years",{"count":128,"type":21},144,[53],"The purpose of this study was to investigate the effect of bupivacaine liposomes on postoperative pain in TKA ( total knee replacement ) patients.The main questions answered are:\n\n1. Is bupivacaine liposomes superior to bupivacaine in femoral triangle block or adductor block in terms of 72 hours opioid consumption after knee replacement\n2. Which block method(Femoral triangle block or adductor block) combined with bupivacaine liposome was more effective in alleviating pain score and 72 hours opioid consumption after total knee surgery.\n\ninvestigators will investigate the effect of bupivacaine liposomes combined with bupivacaine and pure bupivacaine on pain after total knee arthroplasty using femoral triangle block or adductor block.\n\nParticipants will:\n\n1. Receive liposomal bupivacaine or bupivacaine as a regional anesthetic for femoral triangle block or adductor block under ultrasound guidance.\n2. Undergo total knee replacement surgery under spinal anesthesia.\n3. Follow-up within 72 hours after surgery , opioid consumption, NRS score, PCA（Patient controlled analgesia，PCA） data, first postoperative remedial analgesia time, quadriceps muscle strength and complications were recorded",[132,28],"Knee Arthropathy",[132,134,135,136],"liposome bupivacaine","femoral nerve block","adductor canal block","2024-10-22",{"date":139,"type":33},"2024-10-24",{"date":141,"type":21},"2024-11-05",{"date":143,"type":21},"2025-12-31",{"name":145,"class":40},"Huazhong University of Science and Technology",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":153,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":157,"conditions":158,"keywords":159,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":4},"100551340","non-invasive-distractor-during-knee-arthroscopy-100551340","NCT06458816","Non-Invasive Distractor During Knee Arthroscopy","The Utility of a Non-Invasive Distractor During Arthroscopy of the Knee Joint","Inclusion Criteria:\n\n* Adults ≥ 18 years of age who have capacity to provide informed consent. Eligible participants will include existing patients of Dr. DiStefano who are scheduled to undergo knee arthroscopic surgery to address meniscal pathology. Study risks, benefits and description will be provided and informed consent will be obtained.\n\nExclusion Criteria:\n\n* Patients with prior history of neurovascular deficiency or history of prior injury\n* Patients with a prior history of knee surgery\n* Patients with diagnosed knee ligament laxity or knee instability.\n* Patients that are not cleared for knee arthroscopy",true,{"count":155,"type":21},14,[82],"Patients will be prospectively recruited for knee joint distraction who are undergoing knee arthroscopy. Patient demographics, operative factors, and rates of medical comorbidities will be collected and evaluated. Intraoperative arthroscopic images will be evaluated by the attending Orthopaedic surgeon with standard and testing mechanism and a measuring device will be used to measure the distance between the femur and tibia in the medial and lateral compartments.",[28,132],[160,161,162,163],"arthroscopy","knee joint distraction","non invasive","sports medicine","2024-06-10",{"date":166,"type":33},"2024-06-14",{"date":168,"type":21},"2024-06",{"date":170,"type":21},"2025-01",{"name":172,"class":40},"The Taylor Collaboration",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":126,"enrollmentInfo":180,"targetDuration":4,"studyType":22,"phases":182,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":4},"100537976","comparison-of-two-robotic-assisted-total-knee-arthroplasty-systems-100537976","NCT06284824","Comparison of Two Robotic-Assisted Total Knee Arthroplasty Systems","Prospective, Randomized, Single-center Study Comparing the Stryker MAKO™ Robotic-Arm Assisted Total Knee Arthroplasty and the DePuy VELYS™ Robotic-Assisted Solution for Total Knee Arthroplasty.","Inclusion Criteria:\n\n* Patient must be a candidate for primary TKA (either Stryker Triathlon with MAKO Robotic-Arm or DePuy Attune with VELYS Robotic-Assistance).\n* Individuals who are able to speak, read, and comprehend the Institutional Review Board approved Informed Consent Document and willing and able to provide informed patient consent for participation in the study and have authorized the transfer of information to the Sponsor.\n* Individuals who are willing and able to complete follow up visits, questionnaires, and radiographic evaluations as specified by the study protocol.\n* Individuals who are male or non-pregnant female age 18-80 years at time of device implantation.\n* Patient has a diagnosis of primary osteoarthritis or degenerative joint disease of the knee.\n\nExclusion Criteria:\n\n* Patient has a Body Mass Index (BMI) \\> 40.\n* Patient has been diagnosed with osteoporosis or displays poor bone quality per the discretion of the investigator.\n* Patient has an active or suspected latent infection in affected knee joint. Patient has neuromuscular or neurosensory deficiency.\n* Patient is diagnosed with systemic disease or metabolic disorder (e.g., Lupus, Charcot's. Paget's).\n* Subject is a woman who is pregnant or lactating.\n* Patient has a contralateral amputation.\n* Patient's affected knee has a flexion contracture greater than 15 degrees.\n* Patient has history of post operative arthrofibrosis.\n* Patient's affected knee has a partial knee arthroplasty.\n* Patient has undergone contralateral TKA within the last three months.\n* Patient is currently involved in any personal injury litigation, medical-legal, or worker's compensation claims.\n* Patient who is bedridden per the discretion of the investigator.\n* Patient has a medical condition with less than 2 years of life expectancy.",{"count":181,"type":21},120,[82],"The goal of this prospective study is to compare two different knee replacement robots. This study will look at patient reported outcome measures and data collected during the operation. The main questions this study aims to answer include:\n\n* Will the patient reported outcomes differ between the two groups?\n* Will the intraoperative data differ between the two groups? Participants will undergo total knee replacement with one of the two robots, complete standardized surveys, and have x-rays taken.",[56,28,185],"Knee Disease",[187,188,189],"robotic assistance","arthroplasty","TKA","2024-04-15",{"date":192,"type":33},"2024-04-17",{"date":194,"type":21},"2024-05",{"date":196,"type":21},"2027-05",{"name":198,"class":199},"Southeast Orthopedic Specialists","NETWORK",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":16,"minAge":207,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":22,"phases":209,"briefSummary":210,"conditions":211,"keywords":213,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":4},"100425880","follow-up-study-for-participants-of-jointstem-investigator-initiated-trial-by-arthroscopy-100425880","NCT04825730","Follow-up Study for Participants of Jointstem Investigator Initiated Trial by Arthroscopy","Long-Term Extension Study of Investigator Initiated Trial to Evaluate Cartilage Regeneration by Arthroscopy in Patients With K-L Grade III Knee Osteoarthritis After 『JOINTSTEM』 Administration","Inclusion Criteria:\n\n* Participants of Jointstem IIT by arthroscopy (BS-JS-IIT1)\n* Participants who signed informed consent document of this study\n\nExclusion Criteria:\n\n* No applicable","20 Years",{"count":155,"type":21},[82],"This clinical trial is conducted to assess the long-term safety of \"jointstem\" in patients with degenerative knee arthritis who participated in the previous BS-JS-IIT1 investigator initiated trial.",[212,28],"Degenerative Arthritis",[214,215,216,217,218,219,220],"Stem cell","Adipose tissue derived mesenchymal stem cell","Osteoarthritis","degenerative arthritis","long term","Biostar","Rbio","2022-09-26",{"date":223,"type":33},"2022-09-28",{"date":225,"type":21},"2023-12-01",{"date":227,"type":21},"2029-12-31",{"name":229,"class":230},"R-Bio","INDUSTRY"]